See more : CapitaLand Investment Limited (9CI.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Inari Medical, Inc. (NARI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inari Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Emergent BioSolutions Inc. (0IGA.L) Income Statement Analysis – Financial Results
- ASI INDUSTRIES LIMITED (ASIIL.BO) Income Statement Analysis – Financial Results
- Protektor S.A. (PRT.WA) Income Statement Analysis – Financial Results
- Investcorp India Acquisition Corp (IVCAW) Income Statement Analysis – Financial Results
- Vertu Motors plc (VTMTF) Income Statement Analysis – Financial Results
Inari Medical, Inc. (NARI)
About Inari Medical, Inc.
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 493.63M | 383.47M | 276.98M | 139.67M | 51.13M | 6.83M |
| Cost of Revenue | 59.07M | 44.51M | 24.76M | 13.11M | 5.91M | 1.28M |
| Gross Profit | 434.56M | 338.97M | 252.23M | 126.56M | 45.22M | 5.55M |
| Gross Profit Ratio | 88.03% | 88.39% | 91.06% | 90.62% | 88.44% | 81.24% |
| Research & Development | 87.53M | 74.22M | 51.02M | 18.40M | 7.22M | 3.99M |
| General & Administrative | 349.46M | 291.89M | 190.02M | 89.41M | 37.20M | 10.70M |
| Selling & Marketing | 1.20M | 957.00K | 344.00K | 333.00K | 90.00K | 86.00 |
| SG&A | 361.06M | 292.84M | 190.37M | 89.75M | 37.20M | 10.70M |
| Other Expenses | 0.00 | 356.00K | -18.00K | -662.00K | -205.17K | -133.00K |
| Operating Expenses | 448.60M | 367.06M | 241.38M | 108.15M | 44.42M | 14.69M |
| Cost & Expenses | 507.66M | 411.57M | 266.14M | 121.25M | 50.33M | 15.97M |
| Interest Income | 15.61M | 1.85M | 154.00K | 484.00K | 89.11K | 92.00K |
| Interest Expense | 196.00K | 294.00K | 295.00K | 1.14M | 920.46K | 887.00K |
| Depreciation & Amortization | 10.74M | 7.64M | 4.53M | 1.49M | 629.52K | 283.05K |
| EBITDA | 15.19M | -18.25M | 15.51M | 16.41M | 358.15K | -8.98M |
| EBITDA Ratio | 3.08% | -4.90% | 3.96% | 13.06% | 2.54% | -130.30% |
| Operating Income | -14.03M | -28.10M | 6.67M | 18.42M | 801.49K | -9.14M |
| Operating Income Ratio | -2.84% | -7.33% | 2.41% | 13.19% | 1.57% | -133.84% |
| Total Other Income/Expenses | 18.28M | 1.91M | -159.00K | -4.63M | -1.99M | -1.01M |
| Income Before Tax | 4.25M | -26.19M | 10.69M | 13.79M | -1.19M | -10.15M |
| Income Before Tax Ratio | 0.86% | -6.83% | 3.86% | 9.87% | -2.33% | -148.67% |
| Income Tax Expense | 5.88M | 3.08M | 845.00K | -912.00K | 715.29K | -126.00K |
| Net Income | -1.64M | -29.27M | 9.84M | 13.79M | -1.91M | -10.15M |
| Net Income Ratio | -0.33% | -7.63% | 3.55% | 9.87% | -3.73% | -148.67% |
| EPS | -0.03 | -0.55 | 0.20 | 0.43 | -0.04 | -0.23 |
| EPS Diluted | -0.03 | -0.55 | 0.18 | 0.27 | -0.04 | -0.23 |
| Weighted Avg Shares Out | 56.77M | 52.84M | 49.82M | 32.03M | 48.18M | 44.95M |
| Weighted Avg Shares Out (Dil) | 56.77M | 52.84M | 55.59M | 51.55M | 48.18M | 44.95M |
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
NARI Stock Likely to Gain Following Reimbursement Approval in Japan
Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
Inari Medical Announces Joint Venture in Greater China
PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism
Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y
Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript
Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates
Inari Medical Reports Third Quarter 2024 Financial Results
Okami Medical Announces Closing Of $32.5M Financing
Source: https://incomestatements.info
Category: Stock Reports